Published in ACS Chem Biol on September 19, 2006
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell (2007) 5.09
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A (2008) 3.27
A specificity map for the PDZ domain family. PLoS Biol (2008) 3.16
SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res (2008) 1.87
Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc (2007) 1.70
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One (2012) 1.60
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew Chem Int Ed Engl (2010) 1.29
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res (2008) 1.24
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. Cancer Res (2011) 1.13
Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J Med Chem (2008) 1.11
Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. J Biol Chem (2009) 1.09
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem (2009) 1.08
Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol (2012) 1.06
Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins. J Biol Chem (2009) 1.03
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. J Med Chem (2011) 1.00
Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. J Med Chem (2009) 0.96
Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. J Am Chem Soc (2009) 0.96
IAP proteins as targets for drug development in oncology. Onco Targets Ther (2013) 0.95
Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. J Med Chem (2008) 0.95
Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol (2011) 0.94
X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol (2011) 0.92
Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts. J Am Soc Nephrol (2013) 0.92
Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. Biochemistry (2008) 0.91
Cyclopeptide Smac mimetics as antagonists of IAP proteins. Bioorg Med Chem Lett (2010) 0.91
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem (2013) 0.90
Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem (2010) 0.89
Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol (2013) 0.89
Synthetic mimetics of protein secondary structure domains. Philos Trans A Math Phys Eng Sci (2010) 0.88
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol (2014) 0.87
Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. J Med Chem (2008) 0.86
Using Protein Motion to Read, Write, and Erase Ubiquitin Signals. J Biol Chem (2015) 0.86
Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. Protein Sci (2010) 0.85
Targeting apoptosis signaling pathways for anticancer therapy. Front Oncol (2011) 0.85
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer (2014) 0.84
Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther (2013) 0.83
Nucleotide composition of cellular internal ribosome entry sites defines dependence on NF45 and predicts a posttranscriptional mitotic regulon. Mol Cell Biol (2012) 0.83
A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. J Med Chem (2013) 0.81
Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS One (2012) 0.81
Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells. ACS Chem Biol (2014) 0.80
Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget (2016) 0.78
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol (2017) 0.78
Design and synthesis of a simplified inhibitor for XIAP-BIR3 domain. Bioorg Med Chem Lett (2009) 0.76
The structure of XIAP BIR2: understanding the selectivity of the BIR domains. Acta Crystallogr D Biol Crystallogr (2013) 0.76
Effect of Second mitochondria-derived activator of caspase in combination with Docetaxel on lung cancer cell A549. Int J Clin Exp Med (2015) 0.75
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res (2017) 0.75
Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget (2016) 0.75
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov (2012) 3.88
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 3.54
Design and implementation of a secure wireless mote-based medical sensor network. Sensors (Basel) (2009) 2.83
HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis (2013) 2.82
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J Biol Chem (2005) 2.68
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS. J Infect Dis (2005) 2.47
Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem (2001) 2.45
c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J (2010) 2.33
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science (2014) 2.23
Risk Factors Associated with Left-Sided Cardiac Valve Calcification: A Case Control Study. Cardiology (2016) 2.04
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J (2009) 1.94
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
The development of HIV/AIDS surveillance in China. AIDS (2007) 1.86
Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J Pathol (2010) 1.82
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
A radar-enabled collaborative sensor network integrating COTS technology for surveillance and tracking. Sensors (Basel) (2012) 1.65
The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res (2007) 1.63
Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol (2009) 1.60
The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF. J Biol Chem (2002) 1.59
TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 1.59
Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol (2008) 1.59
The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure (2012) 1.57
Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. Am J Pathol (2009) 1.54
Hybrid male sterility in rice controlled by interaction between divergent alleles of two adjacent genes. Proc Natl Acad Sci U S A (2008) 1.52
Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity. ACS Chem Biol (2012) 1.50
Local Rank Inference for Varying Coefficient Models. J Am Stat Assoc (2009) 1.45
Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. J Invasive Cardiol (2002) 1.44
Detailed exposure assessment for a molecular epidemiology study of benzene in two shoe factories in China. Ann Occup Hyg (2004) 1.44
Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics (2010) 1.43
Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res (2005) 1.42
Prevalence of HIV infection and predictors for syphilis infection among female sex workers in southern China. Southeast Asian J Trop Med Public Health (2009) 1.42
Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 1.39
Gender-specific response to isoflurane preconditioning in focal cerebral ischemia. J Cereb Blood Flow Metab (2007) 1.38
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem (2004) 1.38
Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin Cancer Res (2011) 1.38
Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med (2006) 1.36
(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle (2008) 1.36
No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes (2004) 1.35
Sub-retinal drusenoid deposits in human retina: organization and composition. Exp Eye Res (2008) 1.33
Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science (2011) 1.32
The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J Biol Chem (2006) 1.32
Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J (2005) 1.31
The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One (2008) 1.29
Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res (2008) 1.28
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol (2002) 1.27
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem (2012) 1.27
Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophy. Exp Eye Res (2011) 1.25